News

Philips completes the acquisition of BioTelemetry, Inc.

Combination of Philips and BioTelemetry results in a global leader in patient care management solutions for the hospital and the home

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote cardiac diagnostics and monitoring. BioTelemetry’s financial results will be consolidated as part of Philips’ Connected Care business segment as of February 9, 2021.

Philips successfully completes tender offer for BioTelemetry, Inc.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has successfully completed its previously announced tender offer (the “Offer”) to purchase all outstanding shares of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote cardiac diagnostics and monitoring for USD 72.00 per share in cash. At 12:00 midnight, New York time, on February 9, 2021 (one minute after 11:59 P.M., New York time, on February 8, 2021), the Offer expired as scheduled and was not extended. Philips expects to complete the acquisition of BioTelemetry later today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. American Stock Transfer & Trust Company, LLC, the depositary for the

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

Posts Record Quarterly Revenue Amidst Rapid Recovery MALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020. Quarter Highlights Recognized quarterly total revenue of $114.7 million Reached 3.0% year-over-year quarterly revenue growth, despite the impact of COVID-19 Reported quarterly GAAP net income of $6.7 million, or 5.9% of total revenue Realized quarterly adjusted EBITDA of $30.6 million, or 26.7% of total revenue Acquired Remote Patient Monitoring (“RPM”) assets from a subsidiary of Centene Corporation President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on October 29, 2020

MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time. BioTelemetry, Inc. will host an earnings conference call on Thursday, October 29, at 5:00 PM Eastern Time.  The call will be webcast on the investor information page of our website, investors.gobio.com.  The call will be archived on our website for at least two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research

BioTelemetry, Inc. Acquires Remote Patient Monitoring Platform from Centene Subsidiary

Expands relationship to serve Centene members MALVERN, Pa., July 29, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced it has acquired the On.Demand™ remote patient monitoring (RPM) and coaching platform, operated by Envolve People Care, Inc., a Centene Corporation subsidiary.  This acquisition adds chronic RPM and coaching solutions to BioTelemetry’s current suite of acute care connected health products and services, focusing specifically on diabetes, hypertension and chronic heart failure. As part of this acquisition, and under the companies’ strategic partnership agreement, BioTelemetry becomes the exclusive provider of diabetes RPM services to Centene Medicaid members currently utilizing, implementing or engaged to implement the

BioTelemetry, Inc. to Release Second Quarter 2020 Earnings Results on July 30, 2020

MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc.(NASDAQ:BEAT) will release its second quarter 2020 earnings on Thursday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, July 30, 2020.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on the website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment

BioTelemetry, Inc. Reports First Quarter 2020 Financial Results

Announces Record Quarterly Revenue MALVERN, Pa., May 06, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended March 31, 2020. Quarter Highlights Recognized quarterly revenue of $113.0 million Reached 8.7% year-over-year quarterly revenue growth Achieved 31st consecutive quarter of year-over-year revenue growth Reported quarterly GAAP net income of $7.1 million, or 6.3% of revenue Realized quarterly adjusted EBITDA of $29.5 million, or 26.1% of revenue President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “I would like to first express my sincere gratitude to the entire BioTelemetry team and to our

BioTelemetry, Inc. to Release First Quarter 2020 Earnings Results on May 6, 2020

MALVERN, Pa., April 29, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2020 earnings on Wednesday, May 6 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, May 6, 2020.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on the website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original

BioTelemetry, Inc. to Move to Virtual-only Annual Stockholder Meeting for 2020

MALVERN, Pa., April 27, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that its 2020 Annual Meeting of Stockholders will be held virtually, moving away from an in-person event due to the evolving nature of the COVID-19 pandemic. Virtual meeting date:  Friday, May 8, 2020 Virtual meeting time:  8:30 a.m. EDT Virtual meeting link:  www.virtualshareholdermeeting.com/BEAT2020 Stockholders of record at the close of business March 10, 2020, are invited to vote their shares and register for the meeting at www.virtualshareholdermeeting.com/BEAT2020 using the instructions provided with their proxy materials that were issued beginning March 24, 2020.  Stockholders may submit questions in advance when